🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John C. Araujo

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-9361-3364

Also affiliated with Instituto de Pesquisas Energéticas e Nucleares, National Nuclear Energy Commission

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
2.5Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0479
Top 13%
1.6DataRank
Top 13%85 citations

Jun Yang, Peter D.A. Shepherd, Elsa M. Li-Ning-Tapia, Estefanía Labanca, Ganiraju C. Manyam +18 more

Papers

Driven by 8 papers — median percentile 71. Top paper: “The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development”.

The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0479
Top 13%
1.6DataRank
Top 13%85 citations

Jun Yang, Peter D.A. Shepherd, Elsa M. Li-Ning-Tapia, Estefanía Labanca, Ganiraju C. Manyam +18 more

Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2438
Top 29%
0.698DataRank
Top 29%27 citations

Estefanía Labanca, Peter D.A. Shepherd, Jiabin Dong, Jun Yang, Xiaofei Song +20 more

A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer

European Journal of Cancer(2020)10.1016/j.ejca.2019.12.027
N/A
0.435DataRank · unranked
7 citations

Nicholas Spetsieris, Justin A. Weldon, Alexandros Tsikkinis, Anh Hoang, Ana M. Aparicio +14 more

A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2020.05.013
N/A
0.425DataRank · unranked
16 citations

Myrto Boukovala, Justin A. Weldon, Alexandros Tsikkinis, Anh Hoang, Ana M. Aparicio +15 more

Integrative analysis of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX)

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.07.21.500652
Top 70%
0.165DataRank
Top 70%2 citations

Estefanía Labanca, Xiaofei Song, Jun Yang, Peter D.A. Shepherd, Jiabin Dong +18 more

Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis

European Urology Oncology(2025)10.1016/j.euo.2025.04.015
N/A
0DataRank · unranked
0 citations

Rebecca S. Tidwell, Brian F. Chapin, Deborah Harris, Miao Zhang, Louis L. Pisters +11 more

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02661
N/A
0DataRank · unranked
29 citations

Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher J. Logothetis +15 more

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1917
N/A
0DataRank · unranked
2 citations

John F. Ward, Wayne L. Hofstetter, David C. Rice, José A. Karam, Louis L. Pisters +24 more